Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SuperSynbiotics is a Swedish biotechnology and health-tech company focused on the development and commercialization of advanced synbiotic dietary supplements. The company's core technology is based on over 30 years of research by Professor Stig Bengmark, specifically the Synbiotic 2000 formula which combines high doses of lactic acid bacteria with bioactive fibers. Their products are designed to strengthen the gut microbiome, reduce systemic inflammation, and support the immune system. SuperSynbiotics operates primarily in the consumer healthcare space, providing evidence-based microbial therapies backed by numerous clinical studies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SuperSynbiotics.